- Home
- PHAR vs ANAB Comparison
PHAR vs ANAB Comparison
Compare PHAR & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ANAB
- Stock Information
- Founded
- PHAR 1988
- ANAB 2005
- Country
- PHAR Netherlands
- ANAB United States
- Employees
- PHAR N/A
- ANAB N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- ANAB Health Care
- Exchange
- PHAR Nasdaq
- ANAB Nasdaq
- Market Cap
- PHAR 951.7M
- ANAB 1.0B
- IPO Year
- PHAR N/A
- ANAB 2017
- Fundamental
- Price
- PHAR $13.18
- ANAB $36.00
- Analyst Decision
- PHAR Strong Buy
- ANAB Buy
- Analyst Count
- PHAR 3
- ANAB 12
- Target Price
- PHAR $30.00
- ANAB $63.30
- AVG Volume (30 Days)
- PHAR 9.7K
- ANAB 344.1K
- Earning Date
- PHAR 11-06-2025
- ANAB 11-04-2025
- Dividend Yield
- PHAR N/A
- ANAB N/A
- EPS Growth
- PHAR N/A
- ANAB N/A
- EPS
- PHAR N/A
- ANAB N/A
- Revenue
- PHAR $339,836,000.00
- ANAB $169,467,000.00
- Revenue This Year
- PHAR $17.70
- ANAB $37.52
- Revenue Next Year
- PHAR $12.25
- ANAB N/A
- P/E Ratio
- PHAR N/A
- ANAB N/A
- Revenue Growth
- PHAR 22.44
- ANAB 196.42
- 52 Week Low
- PHAR $7.31
- ANAB $12.21
- 52 Week High
- PHAR $17.08
- ANAB $39.78
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- ANAB 65.98
- Support Level
- PHAR $13.03
- ANAB $35.82
- Resistance Level
- PHAR $13.43
- ANAB $37.08
- Average True Range (ATR)
- PHAR 0.49
- ANAB 1.83
- MACD
- PHAR -0.10
- ANAB -0.32
- Stochastic Oscillator
- PHAR 23.47
- ANAB 44.20
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).